UNSPSC 51311901: Cromoglicic acid or cromolyn

This classification denotes a mast cell stabilizer with the molecular formula C23H16O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0TK0FS77W, chemically known as 5,5-(2-hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid) but generally known as cromoglicic acid, which bears US NIH Compound Identifier 27686. European Medicines Agency schedules Cromoglicic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06825MIG.

UNSPSC 51311901 Cromoglicic acid or cromolyn, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The three recent opportunities tagged under this code — Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and Minnesota's MMCAP cooperative purchasing RFP for generic pharmaceuticals and OTC products — do not involve cromoglicic acid or related respiratory/allergic-condition medications at all. The code appears to capture a broad set of pharmaceutical and medical product procurements that state and local health agencies are actually conducting, ranging from emergency-response medications and pharmacy benefit program design to multi-state cooperative purchasing of generic drugs and over-the-counter items distributed through authorized wholesalers.

Recent activity spans state health agencies, county health systems, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly delivery to its Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI in early April 2026 to gather vendor capabilities for direct-to-manufacturer pharmaceutical contracting outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed to participating state and local government facilities across Minnesota and Oregon through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with contracts effective July 1, 2026. Given the scope divergence between the code name and actual procurement content, this code shows little relevant recent activity for vendors focused on cromoglicic acid products specifically.